The potential of proteasome inhibition in the treatment of colon cancer

Expert Opinion on Investigational Drugs

Volumn 15, Issue 9, 2006, Pages 1067-1075

  Konstantinopoulos, Panagiotis A ^a,b   Papavassiliou, Athanasios G ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Chemosensitisation; Colon cancer; NF B; Proteasome inhibitors; Radiosensitisation; Ubiquitin proteasome degradation system

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BEVACIZUMAB; BORTEZOMIB; CALPASTATIN; CETUXIMAB; DEXAMETHASONE; FLUOROURACIL; IRINOTECAN; LACTACYSTIN BETA LACTONE; NPI 0052; OXALIPLATIN; PROTEASOME; PROTEASOME INHIBITOR; PROTEINASE INHIBITOR; SULINDAC; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UBIQUITIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD TOXICITY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL CYCLE REGULATION; CELL METABOLISM; CELL MIGRATION; CLINICAL TRIAL; COLON CANCER; DEREGULATION; DIARRHEA; DNA REPAIR; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TARGETING; DRUG USE; GENETIC TRANSCRIPTION; HEMATOLOGIC MALIGNANCY; HUMAN; META ANALYSIS; MONOTHERAPY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PROTEIN DEGRADATION; REVIEW; SENSORY NEUROPATHY; SYSTEMATIC REVIEW; THROMBOCYTOPENIA;

COLONIC NEOPLASMS; ENZYME INHIBITORS; HUMANS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN BINDING; UBIQUITIN;

EID: 33748199156     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.9.1067     Document Type: Review

References (103)

1. KANE RC, BROSS PF, FARRELL AT, PAZDUR R: Velcade: US FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist (2003) 8:508-513.
2. LUDWIG H, KHAYAT D, GIACCONE G, FACON T: Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer (2005) 104(9):1794-1807.
3. JACKSON G, EINSELE H, MOREAU P, MIGUEL JS: Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treat. Rev. (2005) 31(8):591-602.
4. ADAMS J: The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer (2004) 4(5):349-360.
5. RICHARDSON PG, BARLOGIE B, BERENSON J et al.: Extended follow-up of a Phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer (2006) 106(6):1316-1319.
6. JAGANNATH S, BARLOGIE B, BERENSON J et al: A Phase II study of two doses of bortezomib in relapsed or refractory myeloma. Br. J. Haematol. (2004) 127(2):165-172.
7. RICHARDSON PG, SONNEVELD P, SCHUSTER MW et al: Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators: bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. (2005) 352(24):2487-2498.
8. GOY A, YOUNES A, McLAUGHLIN P et al.: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin. Oncol. (2005) 23:667-675.
9. O'CONNOR OA, WRIGHT J, MOSKOWITZ C et al.: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J. Clin. Oncol. (2005) 23:676-684.
10. BELCH A, KOUROUKIS T, CRUMP M: Phase II trial of bortezomib in mantle cell lymphoma. Blood (2004) 104:175a-176a.
11. DUNLEAVY K, JANIK J, GEA-BANACLOCHE J: Phase I/II study of bortezomib alone and bortezomib with dose-adjusted EPOCH chemotherapy in relapsed or refractory aggressive B-cell lymphoma. Blood (2004) 104:389a (Abstract 1386).
12. ADAMS J, PALOMBELLA VJ, SAUSVILLE EA et al.: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. (1999) 59:2615-2622
13. ADAMS J: Development of the proteasome inhibitor PS-341. Oncologist (2002) 7:9-16.
14. BOCCADORO M, MORGAN G, CAVENAGH J: Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. (2005) 5(1):18.
15. HIDESHIMA T, BRADNER JE, CHAUHAN D, ANDERSON KC: Intracellular protein degradation and its therapeutic implications. Clin. Cancer Res. (2005) 11:8530-8533.
16. MANI A, GELMANN EP: The ubiquitin-proteasome pathway and its role in cancer. J. Clin. Oncol. (2005) 23(21):4776-89.
17. WILK S, ORLOWSKI M: Evidence that pituitary cation-sensitive neutral endopeptidase is a multicatalytic protease complex. J. Neurochem. (1983) 40(3):842-849.
18. KISSELEV AF, CALLARD A, GOLDBERG AL: Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J, Biol. Chem. (2006) 281(13):8582-8590.
19. HIDESHIMA T, RICHARDSON PG, ANDERSON KC: Targeting proteasome inhibition in hematologic malignancies. Rev. Clin. Exp. Hematol. (2003) 7(2):191-204.
20. VOORHEES PM, DEES EC, O'NEIL B, ORLOWSKI RZ: The proteasome as a target for cancer therapy. Clin. Cancer Res. (2003) 9:6316-6325.
21. ADAMS J: The proteasome: structure, function, and role in the cell. Cancer Treat. Rev. (2003) 29(Suppl. 1):3-9.
22. KARIN M, CAO Y, GRETEN FR, LI ZW: NF-κB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer (2002) 2:301-310.
23. KORDES U, KRAPPMANN D, HEISSMEYER V, LUDWIG WD, SCHEIDEREIT C: Transcription factor NF-κB is constitutively activated in acute lymphoblastic leukemia cells. Leukemia (2000) 14:399-402.
24. TRICOT G: New insights into role of microenvironment in multiple myeloma. Lancet (2000) 355:248-250.
25. PATEL NM, NOZAKI S, SHORTLE, NH et al.: Paclitaxel sensitivity of breast cancer cells with constitutively active NF-κB is enhanced by IκBα super-repressor and parthenolide. Oncogene (2000) 19:4159-4169.
26. GEORGE DJ, KAELIN WG Jr: The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N. Engl. J. Med. (2003) 349(5):419-421.
27. UTHOFF SM, EICHENBERGER MR, McAULIFFE TL, HAMILTON CJ, GALANDIUK S: Wingless-type frizzled protein receptor signaling and its putative role in human colon cancer. Mol. Carcinog. (2001) 31(1):56-62.
28. ADAMS J, BEHNKE M, CHEN S et al.: Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg. Med. Chem. Lett. (1998) 8:333-338.
29. ELLIOTT PJ, ZOLLNER TM, BOEHNCKE WH: Proteasome inhibition: a new anti-inflammatory strategy. J. Mol. Med. (2003) 81(4):235-245.
30. PAPANDREOU C, DALIANI KK, NIX D et al.: Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumours with observations in androgen-independent prostate cancer. J. Clin. Oncol. (2004) 22:2108-2121.
31. ORLOWSKI RZ, STINCHCOMBE TE, MITCHELL BS et al.: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. (2002) 20:4420-4427.
32. ADAMS J: Preclinical and clinical evaluation of proteasome inhibitor PS-341 for the treatment of cancer. Curr. Opin. Chem. Biol. (2002) 6(4):493-500.
33. CUSACK JC, LIU R, XIA L, LJUNGMAN D, BAHJAT R, PALLADINO MA: NPI-0052 - a novel orally administered marine product that promotes chemosensitivity in a colon cancer xenograft model via proteasome inhibition. Gastrointestinal Cancers Symposium, Florida, USA (2005):276 (Abstract).
34. HOCHWALD SN, LIND DS, MALATY J, COPELAND EM III, MOLDAWER LL, MacKAY SL: Antineoplastic therapy in colorectal cancer through proteasome inhibition. Am. Surg. (2003) 69(1):15-23.
35. DEJARDIN E, DEREGOWSKI V, CHAPELIER M et al.: Regulation of NF-κB activity by I κB-related proteins in adenocarcinoma cells. Oncogene (1999) 18(16):2567-2577.
36. KONSTANTINOPOULOS PA, VANDOROS GP, SOTIROPOULOU-BONIKOU G, KOMINEA A, PAPAVASSILIOU AG: NF-κB/PPARγ and/or AP-1/PPARγ 'on /off' switches and induction of CBP in colon adenocarcinomas: correlation with COX-2 expression. Int. J. Colorectal Dis. (2006) 132(2):76-84.
37. LUQUE I, GELINAS C: Rel/NF-κB and IκB factors in oncogenesis. Semin. Cancer Biol. (1997) 8(2):103-111.
38. GILMORE TD, KOEDOOD M, PIFFAT KA, WHITE DW: Rel/NF-κB/IκB proteins and cancer. Oncogene (1996) 13(7):1367-78.
39. HARDWICK JC, VAN DEN BRINK GR, OFFERHAUS GJ, VAN DEVENTER SJ, PEPPELENBOSCH MP: NF-κB, p38 MAPK and JNK are highly expressed and active in the stroma of human colonic adenomatous polyps. Oncogene (2001) 20(7):819-827.
40. ADEGBOYEGA PA, OLOLADE O, SAADA J, MIFFLIN R, DI MARI JF, POWELL DW: Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas. Clin. Cancer Res. (2004) 10(17):5870-5879.
41. VANDOROS GP, KONSTANTINOPOULOS PA, SOTIROPOULOU-BONIKOU G et al.: PPAR-γ is expressed and NF-κB pathway is activated and correlates positively with COX-2 expression in stromal myofibroblasts surrounding colon adenocarcinomas. J. Cancer Res. Clin. Oncol. (2006) 132(2):76-84.
42. CUSACK JC Jr, LIU R, HOUSTON M et al.: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-κB inhibition. Cancer Res. (2001) 61(9):3535-3540.
43. YU J, TIWARI S, STEINER P, ZHANG L: Differential apoptotic response to the proteasome inhibitor bortezomib [VELCADE, PS-341] in Bax-deficient and p21-deficient colon cancer cells. Cancer Biol. Tber. (2003) 2(6):694-699.
44. JOHNSON TR, STONE K, NIKRAD M et al.: The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene (2003) 22(32):4953-4963.
45. VAN GEELEN CM, DE VRIES EG, DE JONG S: Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist. Updat. (2004) 7(6):345-358.
46. WANG Q, WANG X, ZHOU Y, EVERS BM: PKCδ-mediated regulation of FLIP expression in human colon cancer cells. Int. J. Cancer (2006) 118(2):326-334.
47. LARA PN Jr, DAVIES AM, MACK PC et al.: Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy. Semin. Oncol. (2004) 31 (1 Suppl. 1):40-46.
48. PEI XY, DAI Y, GRANT S: The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells. Leukemia (2003) 17(10):2036-2045.
49. ZHU H, ZHANG L, DONG F et al.: Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene (2005) 24(31):4993-4999.
50. NIKRAD M, JOHNSON T, PUTHALALATH H, COULTAS L, ADAMS J, KRAFT AS: The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol. Cancer Ther. (2005) 4(3):443-449.
51. GILLISSEN B, ESSMANN F, GRAUPNER V et al.: Induction of cell death by the BH3-only Bcl-2 homolog Nbk/Bik is mediated by an entirely Bax-dependent mitochondrial pathway. EMBO J. (2003) 22(14):3580-3590.
52. MIYAMOTO SM, HUANG TT, WUERZBERGER D: Cellular and molecular responses to topoisomerase I poisons. Exploiting synergy for improved radiotherapy. Ann. NY Acad. Sci. (2000) 922:274-292.
53. RASHEED ZA, RUBIN EH: Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene (2003) 22(47):7296-7304.
54. RAJENDRA R, MALEGAONKAR D, PUNGALIYA P: Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53. J. Biol. Chem. (2004) 279(35):36440-36444.
55. DESAI SD, LI T, RODRIGUEZ-BAUMAN A: Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells. Cancer Res. (2001) 61(15):5926-5932.
56. HUANG TT, WUERZBERGER-DAVIS S, SEUFZER BJ: NF-κB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events. J. Biol. Chem. (2000) 275(13):9501-9509.
57. WANG CY, CUSACK JC, LIU R, BALDWIN AS: Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-κB. Nat. Med. (1999) 5:412-417.
58. CUSACK JC, LIU R, BALDWIN AS: Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-κB activation. Cancer Res. (2000) 60:2323-2330.
59. WANG CY, MAYO MW, KORNELUK RG, GOEDDEL DV, BALDWIN AS: NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science (1998) 281:1680-1683.
60. SHAH SA, POTTER MW, McDADE TP et al.: 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J. Cell. Biochem. (2001) 82:110-122.
61. RAYMOND E, FAIVRE S, CHANEY S, WOYNAROWSKI J, CVITKOVIC E: Cellular and molecular pharmacology of oxaliplatin. Mol. Cancer Ther. (2002) 1:227-235.
62. O'DWYER PJ, JOHNSON SW: Current status of oxaliplatin, in colorectal cancer. Semin. Oncol. (2003) 30(Suppl. 6):78-87.
63. RAKITINA TV, VASILEVSKAYA IA, O'DWYER PJ: Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines results from inhibition of nuclear factor κB signaling. Cancer Res. (2003) 63(24):8600-8605.
64. KONSTANTINOPOULOS PA, PAPAVASSILIOU AG: 17-AAG: mechanisms of antitumour activity. Expert Opin. Investig. Drugs (2005) 14(12):1471-1474.
65. TEBBUTT NC, CATTELL E, MIDGLEY R, CUNNINGHAM D, KERR D: Systemic treatment of colorectal cancer. Eur. J. Cancer (2002) 38(7):1000-1015.
66. WANG W, McLEOD HL, CASSIDY J: Disulfiram-mediated inhibition of NF-κB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int. J. Cancer (2003) 104(4):504-511.
67. UETSUKA H, HAISA M, KIMURA M et al.: Inhibition of inducible NF-κB activity reduces chemoresistance to 5-fluorouracil in human stomach cancer cell line. Exp. Cell Res. (2003) 289(1):27-35.
68. VOBORIL R, HOCHWALD SN, LI J et al.: Inhibition of NF-κB augments sensitivity to 5-fluorouracil/folinic acid in colon cancer. J. Surg. Res. (2004) 120(2):178-188.
69. YANG H, HERMANN JL, LOGOTHETIS CJ: Enhanced induction of prostate carcinoma cell death by inhibition of proteasomal activity using the novel dipeptidyl boronate PS-341 in combination with ionizing radiation; modulation by bcl-2. Clin. Cancer Res. (1999) 5:3770s (Supplement 204).
70. PRASAD AV, MOHAN N, CHANDRASEKAR B, MELTZ ML: Induction of transcription of 'immediate early genes' by low dose ionizing radiation. Radiat. Res. (1995) 143:263-272.
71. WEICHSELBAUM RR, HALLAHAN D, FUKS Z, KUFE D: Radiation induction of immediate early genes: effectors of the radiation-stress response. Int. J. Radiat. Oncol. Biol. Phys. (1994) 30:229-234.
72. RUSSO SM, TEPPER JE, BALDWIN AS Jr et al.: Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-κB. Int. J. Radiat. Oncol. Biol. Phys. (2001) 50(1):183-93.
73. TEICHER BA, ARA G, HERBST R, PALOMBELLA VJ, ADAMS J: The proteasome inhibitor PS-341 in cancer therapy. Clin. Cancer Res. (1999) 5:2638-2645.
74. PERVAN M, PAJONK F, SUN JR, WITHERS HR, McBRIDE WH: Molecular pathways that modify tumor radiation response. Am. J. Clin. Oncol. (2001) 24:481-485.
75. VAN WAES C, CHANG AA, LEBOWITZ PF et al.: Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. (2005) 63(5):1400-1412.
76. McBRIDE WH, IWAMOTO KS, SYLJUASEN R, PERVAN M, PAJONK F: The role of the ubiquitin/proteasome system in cellular responses to radiation. Oncogene (2003) 22(37):5755-5773.
77. KASID U, PFEIFER A, BRENNAN T: Effect of anti-sense c-raf-1 on tumorigenicity and radiation-sensitivity of human squamous carcinoma. Science (1989) 243:1354-1356.
78. BASU S, ROSENWEIG KR, YOUMELL M, PRICE BD: The DNA-dependent protein kinase in the activation of NF-κB following DNA damage. Biochem. Biophys. Res. Commun. (1998) 247:79-83.
79. SAYERS TJ, MURPHY WJ: Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy. Cancer Immunol. Immunother. (2006) 55(1):76-84.
80. LEBLANC HN, ASHKENAZI A: Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ. (2003) 10(1):66-75.
81. BROOKS AD, RAMIREZ T, TOH U et al.: The proteasome inhibitor bortezomib (Velcade™) sensitizes some human tumor cells to Apo2L /TRAIL-mediated apoptosis. Ann. NY Acad. Sci. (2005) 1059:160-167.
82. NENCIONI A, WILLE L, DAL BELLO G et al.: Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells. Clin. Cancer Res. (2005) 11(11):4259-4265.
83. ZHU H, GUO W, ZHANG L et al.: Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Cancer Biol. Ther. (2005) 4(7):781-786.
84. BRESALIER RS: Primary chemoprevention of familial adenomatous polyposis with sulindac: more questions than answers. Gastroenterology (2002) 123:379-381.
85. MINAMI T, ADACHI M, KAWAMURA R, ZHANG Y, SHINOMURA Y, IMAI K: Sulindac enhances the proteasome inhibitor bortezomib-mediated oxidative stress and anticancer activity. Clin. Cancer Res. (2005) 11(14):5248-5256.
86. SUTHEESOPHON K, KOBAYASHI Y, TAKATOKU MA et al.: Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib. Acta Haematol. (2006) 115(1-2):78-90.
87. MIMNAUGH EG, XU W, VOS M et al.: Simultaneous inhibition of hsp 90 and the proteasome promotes protein ubiquitination, causes endoplasmic reticulum-derived cytosolic vacuolization, and enhances antitumor activity. Mol Cancer Ther. (2004) 3:551-566.
88. DENLINGER CE, RUNDALL BK, JONES DR: Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J. Thorac. Cardiovasc. Surg. (2004) 128:740-748.
89. DENLINGER CE, KELLER MD, MAYO MW, BROAD RM, JONES DR: Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. J Thorac. Cardiovasc. Surg. (2004) 127:1078-1086.
90. PEI XY, DAI Y, GRANT S: Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin. Cancer Res. (2004) 10:3839-3852.
91. CORTES J, THOMAS D, KOLLER C et al.: Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin. Cancer Res. (2004) 10(10):3371-3376.
92. AGHAJANIAN C, SOIGNET S, DIZON DS et al.: A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. (2002) 8(8):2505-2511.
93. LONIAL S, WALLER EK, RICHARDSON PG: Evaluation of the severity and risk of thrombocytopenia with bortezomib therapy in relapsed and refractory multiple myeloma. Hematol. J. (2004) 5:S130-S131 (Abstract 371).
94. RICHARDSON PG, BRIEMBERG H, JAGANNATH S: Characterization and reversibility of peripheral neuropathy in patients with advanced multiple myeloma treated with bortezomib (VELCADE™). The SUMMIT and CREST Study Group. Hematol. J. (2004) 5:S129 (Abstract 368).
95. MacKAY H, MAJOR P, TOWNSLEY C et al.: A Phase II trial of the proteosome inhibitor PS-341 in patients with metastatic colorectal cancer. American Society of Clinical Oncology (2004):3109 (Abstract).
96. RYAN DP, O'NEIL B, LIMA CR et al.: Phase I dose-escalation study of the proteasome inhibitor, bortezomib, plus irinotecan in patients with advanced solid tumors. American Society of Clinical Oncology (2003):915 (Abstract).
97. SUPKO JG, EDER JR, LYNCH TJ et al.: Pharmacokinetics of irinotecan and the proteasome inhibitor bortezomib in adult patients with solid malignancies. American Society of Clinical Oncology (2003):544 (Abstract).
98. DRAGOVICH T, LENZ HJ, ROCHA LIMA CMS et al.: Bortezomib ± irinotecan in relapsed/refractory colorectal cancer (CRC): Interim analysis results from Phase (ph) 2b study. American Society of Clinical Oncology (2004):3591 (Abstract).
99. CHANG R, BERIC A, LIEBES LF et al.: A Phase I study of oxaliplatin (OX) in combination with bortezomib (B) in patients with advanced malignancy. American Society of Clinical Oncology (2005):9678 (Abstract).
100. CHUA YJ, CUNNINGHAM D: Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer. Clin. Colorectal Cancer (2005) 5(Suppl. 2):S81-S88.
101. MARSHALL J: The role of bevacizumab as first-line therapy for colon cancer. Semin. Oncol. (2005) 32(6 Suppl. 9):S43-S47.
102. HIDESHIMA T, RICHARDSON P, CHAUHAN D et al.: The proteasome inhibitor bortezomib inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. (2001) 61:3071-3076.
103. 2-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin. Cancer Res. (2003) 9:1145-1154.